secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001493152-26-008650
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hepion in-licenses ctRNA biomarker assay for early HCC detection from Cirna Diagnostics
--------------------------------------------------------------------------------

- Upfront $50K, milestones up to $2.35M, sales milestones up to $4.5M, low single-digit royalty.
- Assay detects mutant circulating tumor RNA (ctRNA) for early HCC diagnosis in high-risk cirrhosis patients.
- Complements Hepion's mSEPT9 PCR assay; strategic shift to liquid biopsy diagnostics.
- Global liquid biopsy market ~$10B; plans CLIA lab partnerships and eventual FDA submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226008650/0001493152-26-008650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226008650/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-008650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer